Startup Showcase: DeepUll – Revolutionizing Early-Stage Sepsis Diagnosis

Introducing the Biotech Company from Barcelona, Spain, Developing a New Diagnostic System for Early-Stage Sepsis Condition.
Share This

In this Startup Showcase, we will introduce DeepUll, a biotech company from Barcelona, Spain, that is focused on developing a new diagnostic system for early-stage sepsis condition. With their innovative proposal and cutting-edge technology, DeepUll aims to revolutionize the way we diagnose and treat sepsis, which is one of the most critical conditions in modern medicine.


Sepsis is a life-threatening condition that occurs when the body’s response to an infection damages its tissues and organs. According to the World Health Organization (WHO), sepsis affects more than 30 million people worldwide every year, with a mortality rate of up to 30%. Early diagnosis and prompt treatment are crucial for the management of sepsis, but the current diagnostic methods are often time-consuming, inaccurate, and expensive.

This is where DeepUll comes in. By leveraging the latest advancements in biotechnology and artificial intelligence, DeepUll has developed a new diagnostic system that can quickly identify the pathogens and offer the antibiogram within a few hours. Moreover, the system can learn about the patient’s immunological and functional status, enabling doctors to predict the future appearance and evolution of sepsis within a short period of time and provide a suitable clinical response even before the symptoms arise.

The DeepUll Diagnostic System

The DeepUll diagnostic system is based on a proprietary technology that combines microbiology, immunology, and artificial intelligence. The system uses a microfluidic chip that can isolate and culture the pathogens from a blood sample in a matter of hours. The chip is connected to a software platform that can analyze the data and provide an antibiogram, which is a report that shows which antibiotics are effective against the identified pathogens. The system can also analyze the patient’s immune response and provide insights into the patient’s immunological and functional status.

The DeepUll diagnostic system has several advantages over the current diagnostic methods. Firstly, it is faster and more accurate, enabling doctors to start the appropriate treatment sooner. Secondly, it is more cost-effective, as it eliminates the need for multiple tests and reduces the length of hospital stays. Thirdly, it is more personalized, as it provides a comprehensive profile of the patient’s condition, enabling doctors to tailor the treatment to the patient’s specific needs.

The Future of DeepUll

DeepUll’s diagnostic system is currently in the clinical trial phase, and the company aims to obtain regulatory approval in the near future. Once approved, the system will be available to hospitals and clinics worldwide, enabling them to provide faster, more accurate, and more personalized care to sepsis patients.

In addition to sepsis, DeepUll is also exploring other applications of its technology in the field of infectious diseases. The company aims to develop diagnostic systems for other critical conditions such as pneumonia, meningitis, and bloodstream infections.


DeepUll is a biotech company that is poised to revolutionize the way we diagnose and treat sepsis. With its innovative diagnostic system and cutting-edge technology, DeepUll is bringing us one step closer to a world where sepsis is no longer a life-threatening condition. We are excited to see the impact that DeepUll will have on the field of infectious diseases, and we look forward to following their progress.





Your go-to source for the latest technology and venture news from around the world. Stay informed, inspired, and ahead of the curve with us.

Leave a Reply

Your email address will not be published.